Moneycontrol PRO

COVID vaccine | Zydus Cadila plans to roll out ZyCoV-D in 45-60 days following regulatory approvals

Zydus said it can produce up 4-5 lakh doses at its old facilites, and expects to produce 1 crore doses monthly from mid of August, once the new manufacturing facility comes on board likely from the end of July.

July 01, 2021 / 04:46 PM IST
Zydus said the study also shows that ZyCoV-D is safe for children in the age group of 12 to 18 years

Zydus said the study also shows that ZyCoV-D is safe for children in the age group of 12 to 18 years

  • bselive
  • nselive
Todays L/H

Cadila Healthcare (Zydus Cadila) on July 1 said it plans to roll out its COVID-19 vaccine ZyCoV-D in 45-60 days, subject to regulatory approvals and manufacturing scale-up.

The company has filed an application with the Drug Controller General of India (DCGI) seeking emergency use authorisation (EUA) of the ZyCoV-D vaccine.

Zydus said it can produce 4 to 5 lakh doses at its old facilities and expects to produce one crore doses monthly from mid of August, once the new manufacturing facility, expected to come on board from the end of July, is operational.

"We are aspiring to produce about 5 crore doses by December," said Dr Sharvil Patel, Managing Director, Cadila Healthcare.

On the pricing of the vaccine, Patel said the company will announce it before the commercial launch of the jab.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Patel said the company hasn't stockpiled any doses currently. Zydus has invested in upwards of Rs 400-500 crore involving clinical trials and scaling up of manufacturing

Efficacy data

Zydus Cadila said its COVID-19 vaccine ZyCoV-D demonstrated 66.6 percent efficacy against symptomatic RT-PCR positive cases in the interim analysis.

Patel said the interim efficacy analysis was based on 79-90 RT-PCR positive events of the phase-3 trial.

"India our event data is April-June, all indications are that that is the only prevalent strain in the country. Of Seropositive RT-PCR cases that we have done, we did a subset analysis of randomly selecting about one-third of them, all of them have been delta positive cases," Patel said.

Zydus said no moderate cases of COVID-19 disease was observed in the vaccine arm post administration of the third dose suggesting 100 percent efficacy for moderate disease. Zydus said it has found no severe cases or deaths due to COVID-19 occurred in the vaccine arm after administration of the second dose of the vaccine.

The company said it would take about 4-6 months to publish peer-reviewed phase-3 data.

Please read here more about the filing
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jul 1, 2021 04:46 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark